Daniel Tennenbaum, MD

Articles by Daniel Tennenbaum, MD

Daniel Tennenbaum, MDExpert Interviews | December 19, 2022
Dr. Daniel Tennenbaum interviews Dr. Catherine H. Marshall on trends in managing advanced and metastatic prostate cancer.
Read More
Daniel Tennenbaum, MDJournal | November 22, 2022
Up to one-third of all UTUC patients present with variant histology, such as squamous or micropapillary features.
Andrew J. Armstrong, MD, ScM, FACPRLT-PSMA | November 15, 2022
Andrew Armstrong, MD ScM FACP, is interviewed by Daniel Tennenbaum, MD on new research in phenotypic precision medicine.
Daniel Tennenbaum, MDRLT-PSMA | October 27, 2022
Andrew Armstrong, MD ScM FACP, is interviewed by Daniel Tennenbaum, MD on the role of pain in prostate cancer.
Daniel Tennenbaum, MDRLT-PSMA | October 25, 2022
Neil Desal, MD, MHS, is interviewed by Daniel Tennenbaum, MD, on the use of PSMA-PET in intermediate risk prostate cancer.
Daniel Tennenbaum, MDRLT-PSMA | October 25, 2022
Neil Desal, MD, MHS, is interviewed by Daniel Tennenbaum, MD, on the use of PSMA-PET in intermediate risk prostate cancer.
Daniel Tennenbaum, MDJournal | October 24, 2022
A guide to hereditary RCCs and their syndromes, as well as the relevant recommended guidelines for diagnosis and management.
Daniel Tennenbaum, MDRLT-PSMA | October 3, 2022
Andrew Armstrong, MD ScM FACP, is interviewed by Daniel Tennenbaum, MD on the role of precision medicine in prostate cancer.
Daniel Tennenbaum, MDJournal | September 27, 2022
Limited evidence of the feasibility of robot-assisted laparoscopic radical nephrectomy with IVC thrombectomy exists.
Daniel Tennenbaum, MDJournal | August 24, 2022
A report examines the correlation between family history of prostate cancer and risk of progression after prostatectomy.
Daniel Tennenbaum, MDJournal | July 27, 2022
The standard of care transurethral resection for bladder tumors is compared with en bloc resections for urologic procedures.
Daniel Tennenbaum, MDJournal | June 24, 2022
Professor Catherine Marshall gives insight on the recent shifts in management of mHSPC and compares therapies.
Daniel Tennenbaum, MDRLT-PSMA | May 20, 2022
Early identification of biochemical recurrence is a major challenge for post-radical prostatectomy surveillance.
Daniel Tennenbaum, MDmCSPC | May 20, 2022
The treatment of CSPC has been revolutionized by the advent of apalutamide and enzalutamide in this setting.
Daniel Tennenbaum, MDRLT-PSMA | December 10, 2021
Diagnostic accuracy of 68Ga-PSMA-PET/MRI is comparable with mpMRI for patients undergoing primary staging of prostate cancer.
Daniel Tennenbaum, MDRLT-PSMA | December 10, 2021
18F-PSMA-1007 PET/CT successfully detects pathological lesions in patients with high PSA levels after radical prostatectomy.
Daniel Tennenbaum, MDRLT-PSMA | December 10, 2021
Researchers say 18F-PSMA-1007 PET/CT can identify distant metastasis in prostate cancer.